继承者们

工信部：鸿蒙手机操作系统成为世界第三大手机操作系统，开源鸿蒙生态设备累计超 13.5 亿台_我的网站

一 | (ECNS) -- China's pharmaceutical industry accelerated innovation in the first half of this year, with domestic companies steadily improving their R&D capabilities and growth momentum continuing to strengthen, data showed. China's first broad-spectrum targeted anticancer drug entered clinical use at major hospitals across the country this year. It took only eight months to go from submission to market approval. A total of 38 innovative drugs were approved for marketing in China in the first half, of which 31 were developed domestically, more than 80% of the total. Eleven drugs featuring new targets or new mechanisms were all developed independently by domestic companies, producing a number of world-first innovations. By the end of 2025, China had 4,751 innovative drugs under development, one-third of the global total and the largest pipeline of any country. Behind this concentration of results lies a steadily strengthening industrial base. China has a complete pharmaceutical supply chain. It is not only the world's largest producer of active pharmaceutical ingredients but has also built a production system covering every pharmaceutical category. This year, digital, intelligent, and green technologies have driven the industry's transformation and upgrading. At a biopharmaceutical company in Shanxi Province, a newly built AI-powered bio-computing center can identify the structures of millions of protein functional domains in a short time, screening out ineffective molecules directly. To date, China has supported 21 pharmaceutical firms in building excellent-level smart factories and has cultivated more than 300 green factories. In the first half, the added value of pharmaceutical enterprises above the designated scale grew 6.4% year on year, and exports held strong. The world's first chemotherapy-sparing drug for gastric cancer, launched this year, had already earned overseas revenue through licensing deals before it reached the market, and is now exported to multiple countries and regions. In the first half, the total value of China's innovative drug out-licensing deals reached $110 billion, the industry's export delivery value grew 9% year on year, and high-value-added products made up nearly 20% of the total. (By Tang Yuxian) 。 8 月 26 日消息，国务院新闻办公室今日举行“开局起步‘十五五’”系列主题新闻发布会，介绍全力抓好“十五五”规划实施，加快推进新型工业化有关情况。工业和信息化部信息通信发展司司长刘郁林在回答相关提问时表示，基础软件是数字社会的“基石”，工业软件是制造业数字化转型的“灵魂”。“十四五”以来，我国基础软件和工业软件的供给能力和应用水平大幅提升。三维计算机辅助设计（CAD）、建模仿真软件等软件产品具备市场竞争力。我国数据库产品数量世界第一。鸿蒙手机操作系统成为世界第三大手机操作系统。开源鸿蒙生态设备累计超 13.5 亿台，“工鸿”“仪鸿”等操作系统在汽车、家电、冶金、石油化工等领域规模化应用。国家级人工智能开源社区汇聚用户 1,100 余万、托管模型超 7 万个。国内人工智能开源大模型全球累计下载量突破 100 亿次。总体来看，软件对制造业的赋能、赋值和赋智作用愈发凸显。据此前报道，8 月 20 日，华为常务董事、产品投资评审委员会主任、终端 BG 董事长余承东宣布，HarmonyOS 6 终端设备数突破 8000 万。